Published in Int J Radiat Oncol Biol Phys on March 16, 2010
Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog (2011) 1.70
ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene (2013) 1.40
MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res (2011) 1.21
P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. Am J Pathol (2011) 0.91
The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables. J Mol Histol (2014) 0.90
Survivin-T34A: molecular mechanism and therapeutic potential. Onco Targets Ther (2010) 0.84
Survivin: a unique target for tumor therapy. Cancer Cell Int (2016) 0.84
Phenethyl isothiocyanate suppresses inhibitor of apoptosis family protein expression in prostate cancer cells in culture and in vivo. Prostate (2011) 0.81
Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study. BMC Cancer (2013) 0.79
Molecular targets for radiation oncology in prostate cancer. Front Oncol (2011) 0.78
Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative. Oncotarget (2016) 0.75
Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model. Korean J Radiol (2016) 0.75
Physcion 8-O-β-glucopyranoside induces mitochondria-dependent apoptosis of human oral squamous cell carcinoma cells via suppressing survivin expression. Acta Pharmacol Sin (2016) 0.75
Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients. Oncol Lett (2016) 0.75
Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms. J Mol Histol (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83
Cell migration: integrating signals from front to back. Science (2003) 29.13
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65
Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat Cell Biol (2003) 5.29
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res (2008) 3.92
General mechanisms of metastasis. Cancer (1997) 3.71
Microtubule-organizing centres: a re-evaluation. Nat Rev Mol Cell Biol (2007) 3.28
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
Cell migration at a glance. J Cell Sci (2005) 2.80
Survivin study: what is the next wave? J Cell Physiol (2003) 2.50
Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem (1998) 2.27
The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol (2006) 2.19
Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol (2003) 2.12
Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg (1994) 1.88
Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med (2004) 1.80
Regulation of microtubule stability and mitotic progression by survivin. Cancer Res (2002) 1.74
Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene (2005) 1.68
The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer (2006) 1.67
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res (2006) 1.65
The case for Survivin as mitotic regulator. Curr Opin Cell Biol (2006) 1.59
Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene (2004) 1.54
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res (1997) 1.25
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate (2002) 1.15
Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol (2004) 1.14
Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate (2005) 1.09
10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol (2004) 1.08
Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol (1997) 1.06
Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol (2001) 1.05
Clinical trials in metastatic prostate cancer--has there been real progress in the past decade? Eur J Cancer (2005) 1.01
Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis (2003) 0.94
A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol (2002) 0.93
RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene (2004) 0.91
The basic biology of metastasis. Cancer Treat Res (2004) 0.91
Molecular and genetic prognostic factors of prostate cancer. World J Urol (2003) 0.89
Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int J Radiat Oncol Biol Phys (2008) 0.83
Mechanisms of metastasis suppression by introduction of human chromosome 10 into rat prostate cancer. Asian J Androl (2002) 0.78
Use of a reconstituted basement membrane to study the invasiveness of tumor cells. Adv Exp Med Biol (1992) 0.77
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med (2011) 7.46
Mapping human genetic diversity in Asia. Science (2009) 7.40
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 6.98
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (2013) 5.03
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol (2008) 4.69
Bladder cancer. Lancet (2009) 4.43
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol (2003) 4.33
NFKBIA deletion in glioblastomas. N Engl J Med (2010) 3.96
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology (2002) 3.79
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys (2007) 3.24
Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys (2002) 3.21
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol (2011) 3.17
Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys (2002) 3.15
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol (2007) 2.96
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature (2010) 2.91
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol (2008) 2.72
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys (2006) 2.69
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol (2012) 2.61
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys (2007) 2.55
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology (2013) 2.36
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol (2004) 2.24
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA (2010) 2.16
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008) 2.16
Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys (2010) 2.14
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
The origin and evolution of porcine reproductive and respiratory syndrome viruses. Mol Biol Evol (2005) 2.09
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
A large variation in the rates of synonymous substitution for RNA viruses and its relationship to a diversity of viral infection and transmission modes. Mol Biol Evol (2004) 2.07
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy (2012) 2.03
Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol (2002) 2.00
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Analysis of data errors in clinical research databases. AMIA Annu Symp Proc (2008) 1.99
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Reliabilities of identifying positive selection by the branch-site and the site-prediction methods. Proc Natl Acad Sci U S A (2009) 1.94
Management of complications of prostate cancer treatment. CA Cancer J Clin (2008) 1.91
Proton beams to replace photon beams in radical dose treatments. Acta Oncol (2003) 1.87
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol (2012) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.85
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys (2002) 1.85
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys (2005) 1.83
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology (2009) 1.83
A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Med (2007) 1.81
Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA (2009) 1.81
Transcriptional interferences in cis natural antisense transcripts of humans and mice. Genetics (2007) 1.79
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol (2008) 1.76
Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.75
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst (2009) 1.75
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol (2011) 1.71
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology (2005) 1.71
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys (2010) 1.70
Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys (2005) 1.70
Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene (2005) 1.68
Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci (2008) 1.67
Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol (2004) 1.66